COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Immune Response followingTdap Vaccine in Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04082299
Recruitment Status : Recruiting
First Posted : September 9, 2019
Last Update Posted : November 6, 2019
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Brief Summary:
Pregnancy involves changes in immune response. The investigators aim to evaluate the immune response to Tdap in pregnancy in comparison to non pregnant women usig proteomics and gene sequencing.

Condition or disease
Diphtheria-Tetanus-acellular Pertussis Vaccines

Detailed Description:
Many vaccine-preventable diseases, like influenza, pertussis, and tetanus cause substantial morbidity and mortality in pregnant women, newborns and infants. Immunization during pregnancy has the potential to provide protection to the newborn and infant by the transplacental transfer of vaccine-specific maternal antibodies. However, the immunobiology underlying immunization during pregnancy, that leads to the protection of the newborn are not understood. Current vaccine formulations were designed for and tested in non-pregnant populations; yet substantial immune modulations take place during different stages of pregnancy and potentially can impact the humoral response following maternal immunization. The investigators thus have insufficient data on quantity and quality of the immune response during pregnancy and how this relates to immunity provided from the mother to the newborn. First, The investigators hypothesize that the nature and breadth of the humoral immune response following vaccination differs in pregnant and non-pregnant vaccinees. Next, The investigators hypothesize that the vaccine-specific antibodies that cross the placenta, comprise distinct repertoire features thus, the placenta functions as a differential barrier for antibody transfer. To test these hypotheses, The investigators will use proteomic and genomic/transcriptomic measurements of antibody repertoires in the maternal and cord blood compartments. The measurements will be based on antibody clonal diversity/frequency, V(D)J germline usage and SHM, where we expect to find changes in i) vaccine-specific B cell frequency, antibody clonal diversity, germline usage and SHM in pregnant women and ii) distinct repertoire features in the transplacental vaccine-specific antibody compartment compared the maternal compartment. The investigators will utilize deep sequencing and proteomic technologies to provide, for the first time, insight into the immunobiology of a promising intervention aimed to prevent early life infectious morbidity and mortality and establish new research avenues for vaccine research in vulnerable populations.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 4 Months
Official Title: Immune Response Following Tdap Vaccination in Pregnant vs. Non Pregnant Women
Actual Study Start Date : September 12, 2019
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022

Resource links provided by the National Library of Medicine

Pregnant women
pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
Non pregnant women
Non pregnant women expected to be vaccinate with Tdap vaccine

Primary Outcome Measures :
  1. Immune response following Tdap vaccine [ Time Frame: 4 months ]
    Characterization of immune response following Tdap vaccine.

Biospecimen Retention:   Samples Without DNA
Peripheral blood for Immunoglobulin G analysis, umbilical blood and mother milk.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
pregnant and non pregnant women

Inclusion Criteria for pregnant women (cohort 1):

  • age between 18-45 years
  • pregnant women who expected to have Tdap vaccine
  • Informed Consent Form signature

Inclusion Criteria for non pregnant women (cohort 2):

  • age between 18-45 years
  • non pregnant women who expected to have Tdap vaccine
  • Informed Consent Form signature

Exclusion Criteria (cohort 1 and 2):

  • any background immune diseases- autoimmune conditions or cancer.
  • women who take immunosuppressive/ immunomodulatory medications
  • a patient has received Tdap vaccine in 6 months prior to study entry.
  • no will to signed the Informed Consent Form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04082299

Layout table for location contacts
Contact: Rinat Gabbay-Benziv, Dr +972-4-7744602
Contact: Yariv Wine, PhD +972-3-6408723

Layout table for location information
Hillel Yaffe medical center Recruiting
Hadera, Israel, 3810101
Contact: Osnat Palgi, Bsc    +972-4-7744602   
Sponsors and Collaborators
Hillel Yaffe Medical Center
Layout table for investigator information
Principal Investigator: Rinat Gabbay-Benziv, Dr Hillel Yaffe Medical Center
Layout table for additonal information
Responsible Party: Hillel Yaffe Medical Center Identifier: NCT04082299    
Other Study ID Numbers: 0079-19-HYMC
First Posted: September 9, 2019    Key Record Dates
Last Update Posted: November 6, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Gram-Positive Bacterial Infections
Corynebacterium Infections
Actinomycetales Infections